Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657553 | 0.94 | HTR1A (0.48) | HRH3DRD4HTR1AADRA1APOLB | |
| SCHEMBL5657861 | 0.94 | OPRM1 (0.55) | OPRM1DRD2HTR1APOLBGFER | |
| SCHEMBL5655939 | 0.90 | OPRM1 (0.57) | OPRM1HRH3HRH1DRD4SLC6A4 | |
| SCHEMBL5657619 | 0.90 | HTR7 (0.51) | OPRM1DRD2DRD4ADRA1APOLB | |
| SCHEMBL5657065 | 0.90 | ALDH1A1 (0.51) | OPRM1DRD2HRH1DRD4HTR1A | |
| SCHEMBL5658364 | 0.90 | HTR2A (0.58) | OPRM1DRD2DRD4SLC6A4HTR1A | |
| SCHEMBL5655983 | 0.89 | MAPT (0.53) | OPRM1DRD2DRD4HTR1A | |
| SCHEMBL5655859 | 0.87 | GFER (0.55) | HRH3DRD4HTR1AADRA1APOLB | |
| SCHEMBL5659495 | 0.86 | OPRM1 (0.50) | OPRM1HRH3DRD2HRH1DRD4 | |
| SCHEMBL5655837 | 0.86 | DRD2 (0.63) | DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | claimed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | OPRM1 242/4885HRH3 129/4885DRD2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.